Natus Medical Incorporated (NTUS) News
Filter NTUS News Items
NTUS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NTUS News From Around the Web
Below are the latest news stories about NATUS MEDICAL INC that investors may wish to consider to help them evaluate NTUS as an investment opportunity.
Global Neurology Devices Market Analysis & Forecasts, 2016-2021, 2021-2026F, 2031FDUBLIN , June 22, 2022 /PRNewswire/ -- The "Global Neurology Devices Market Report 2022" report has been added to ResearchAndMarkets.com''s offering. The global neurology devices market is expected to grow from $13.94 billion in 2021 to $15.91 billion in 2022 at a compound annual growth rate (CAGR) of 14.2%. The market is expected to grow to $25.75 billion in 2026 at a compound annual growth rate (CAGR) of 12.8%. Major companies in the neurology devices market include Medtronic Inc., Stryker Corporation, Terumo Corporation, Integra Lifesciences, Boston Scientific Corporation, Penumbra, Inc., B. Braun Group, Nevro, LivaNova, PLC, and Natus Medical. The neurology devices market consists of sales of neurology devices and related services by entities (organizations, sole traders, and partne... |
Natus Medical Announces First Quarter 2022 Financial ResultsQ1-2022 Key ResultsRevenue (millions)$119.8 • Total revenue increased 4.2% compared to Q1 2021• Generated $8.9 million in operating cash flowGAAP EPS$0.06 Non-GAAP EPS$0.22 MIDDLETON, Wis., May 05, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three |
Natus Medical Soars. It’s Being Taken Private by ArchiMed for $1.2 Billion.Shares of Natus Medical were soaring Monday after the company announced it would be acquired by investment firm ArchiMed for approximately $1.2 billion. Natus (ticker: NTUS ) is a maker of medical devices for diagnosing and treating disorders affecting the brain and nervous systems. ArchiMed will pay Natus shareholders $33.50 in cash for each share of common stock they own, a 29% premium to the stock’s closing price on April 14. |
Natus Medical to Be Acquired By ArchiMed in $1.2 Billion DealBy Sam Boughedda |
Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50 per share in cashHighlights: • Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value• Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today th |
Natus Medical to Hold 2022 First Quarter Financial Results Conference Call on May 6thPLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m |
The past five years for Natus Medical (NASDAQ:NTUS) investors has not been profitableNatus Medical Incorporated ( NASDAQ:NTUS ) shareholders should be happy to see the share price up 21% in the last... |
All You Need to Know About Natus Medical (NTUS) Rating Upgrade to BuyNatus Medical (NTUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Natus Medical Announces Fourth Quarter 2021 Financial ResultsQ4-2021 Key ResultsRevenue (millions)$128.7 • Revenue increased 8% compared to Q4 2020• Revenue increased 14% compared to full year 2020• $12.8 million in operating cash flow for Q4 2021• $63.9 million in operating cash flow for the year 2021GAAP EPS$0.05 Non-GAAP EPS$0.47 PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the b |
Natus Medical (NTUS) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseNatus Medical (NTUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |